Resolution at Extraordinary General Meeting of Probi

Regulatory News:

On the extraordinary general meeting of Probi AB (publ) (STO:PROB) held today 29 June 2016, it was resolved to authorise the Board of Directors to resolve on the issue of new shares with preferential right for the company’s shareholders during the period up to the company’s annual general meeting 2017. The total number of shares that may be issued by virtue of the authorisation shall amount to the number of shares corresponding to issue proceeds of approximately SEK 600,000,000, and shall be within the limits of the share capital. The purpose of the authorisation is to enable financing of the company’s acquisition of U.S probiotic company Nutraceutix’s operations. Other terms and conditions for the new share issue shall be determined by the Board.

The information is such that Probi AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.

ABOUT PROBI

Probi AB is a Swedish publicly traded bioengineering company that develops effective and well-documented probiotics. Through its world-leading research, Probi has created a strong product portfolio in the gastrointestinal health and immune system niches. Probi’s products are available to consumers in more than 30 countries worldwide. Probi’s customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. In 2015 Probi had sales of MSEK 216. The Probi share is listed on Nasdaq Stockholm, Small Cap. Probi has about 4,000 shareholders. Read more at www.probi.se.

This information was brought to you by Cision http://news.cision.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160629005587/en/